Search
Methylchloroisothiazolinone
go.drugbank.com/drugs/DB14197ApprovedSensitivity to Methylchloroisothiazolinone may be identified with a clinical patch test. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.
Synonyms: 5-Chloro-N-methylisothiazolin-3-oneEluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalEluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid recept...
Zastaprazan
go.drugbank.com/drugs/DB21524InvestigationalThe usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. … Zastaprazan has a monoisotopic molecular weight of 362.21 Da.
Linaprazan
go.drugbank.com/drugs/DB20602InvestigationalThe usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. … Linaprazan has a monoisotopic molecular weight of 366.21 Da.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
Thioridazine
go.drugbank.com/drugs/DB00679ApprovedWithdrawnThioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).
Synonyms: 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazineFitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770] … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnThe exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
Frangula purshiana bark
go.drugbank.com/drugs/DB15478ApprovedSynonyms: Rhamnus purshiana bark dry extractMixtures: Herbalax Forte No 70 TabEzogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnFDA approved in June 10, 2011 under the name of ezogabine.
Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester